lenalidomide / Generic mfg. - LARVOL DELTA

Administering Tafasitamab, Lenalidomide, and Rituximab for Follicular Lymphoma: A Single-Institution Experience From the Phase 3 inMIND Study (SOHO 2026) - "Experience from Fred Hutch demonstrates that reduced infusion durations for tafasitamab/placebo and rituximab delivered through the described rapid infusion protocol enabled a meaningful reduction in clinic time of >2 hours after cycle 1 day 1. Limiting intervals between pretreatment procedures and infusion would further enable completion of all infusions reliably in a single day. CD: cluster of differentiation, Fred Hutch: Fred Hutchinson Cancer Center, IRR: infusion-related reaction, IV: intravenous."

Clinical • P3 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2, P3 | "Median number of prior treatments was 4.5 (range, 2–6) in Part A and 3 (range, 1–12)in Part B Cohort D. Approximately one-third of the treated patients were exposed to prior T-cell–redirecting therapy, approximately one-third had prior lenalidomide (len) exposure, and approximatelyone-third were refractory to the last regimen received. A higher ORR/CRR and similar tolerability were observed with GOLCA 0.4 mg + R vsGOLCA 0.2 mg + R, including in patients with prior len-based and/or T-cell–redirecting treatment. Thesedata support continued development of GOLCA 0.4 mg + R as a fixed-duration, chemotherapy-free,outpatient option in the ongoing Phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Cardiovascular • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Lymphoma • Neutropenia • Pulmonary Embolism • Respiratory Diseases • CRBN • IKZF1

Real Life Data of Belantamab Mafodotin for Patients with Early Relapsed Multiple Myeloma (IMS 2026) - "Introduction: Belantamab mafodotin (BELA) was recently approved for patients with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line, in combination with bortezomib (BOR) or pomalidomide (POM)...Sixteen (28%) pts received BELA+proteosome inhibitor (PI) (14 BOR, 2 carfilzomib); 30 (52.6%) pts received BELA+immunomodulatory drug (IMiD) (26 POM, 4 lenalidomide (LEN))... Belantamab mafodotin shows significant anti-myeloma activity in early RRMM pts with high rate of daratumumab exposure in a real-world setting with a manageable safety profile."

Clinical • Cardiovascular • Congestive Heart Failure • Febrile Neutropenia • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Myocardial Infarction • Neutropenia • Ophthalmology • Thrombocytopenia

Daratumumab Plus Bortezomib Maintenance After DVMP Induction in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: 3-Year Real-World Outcomes Beyond the ALCYONE Strategy (IMS 2026) - "In real-world practice, the addition of bortezomib to daratumumab maintenance following DVMP induction in transplant-ineligible NDMM patients appears to improve outcomes compared with daratumumab alone, despite inclusion of an older population (average age 7 years higher) and 28% of patients who would not have met ALCYONE trial eligibility criteria. This may represent a valuable alternative for patients intolerant to lenalidomide, though longer follow-up is needed."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM). (ASCO 2026) - P1 | "BVRd had high response rates across all cohorts (≥83%), highlighting the promising efficacy of the regimen. Regimens with higher belamaf induction mDI had the deepest responses, while those with lower induction mDI had milder OEFs. Belamaf dosing with a higher induction DI is optimal to achieve deeper responses, and a lower maintenance DI (i.e., using longer schedules) improves tolerability, PROs, and maintains responses."

Hematological Malignancies • Multiple Myeloma • Ophthalmology • Transplantation

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. (PubMed, N Engl J Med) - P1/2 | "Treatment with ViPOR was associated with durable remissions in patients with specific molecular DLBCL subtypes and was associated with mainly reversible adverse events. (Funded by the Intramural Research Program of the National Cancer Institute and the National Center for Advancing Translational Sciences of the National Institutes of Health and others; ClinicalTrials.gov number, NCT03223610.)."

IO biomarker • Journal • P1 data • P2 data • Cerebral Hemorrhage • CNS Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • BCL6 • MYC

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant – Data from the Myeloma XI Trial (ASH 2022) - "The current analysis suggests that between 4 and 5 years the impact diminished in all patients, earlier in the subgroup of patients MRD-ve after ASCT. Ongoing long term follow up of this and other studies is needed to define the optimal time point at which a randomised trial of stopping or continuing maintenance should be implemented."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Transplantation

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma (SOHO 2026) - P3 | "In 0.2- and 0.4-mg groups, median prior therapy lines were 3 and 3; 32% and 32% had prior lenalidomide; 27% and 29% had prior T-cell-redirecting therapy; and 32% and 32% were refractory to last regimen. Golcadomide + rituximab continued to demonstrate promising efficacy with durable responses and no new safety signals. Efficacy was higher with 0.4 mg vs 0.2 mg, including patients with prior LEN and/or T-cell-redirecting therapies. These results support the phase 3 GOLSEEK-4 study of golcadomide ± rituximab as fixed-duration, chemotherapy-free outpatient treatment in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Follicular Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. (PubMed, J Clin Oncol) - "Dara-KRd, AHCT, and MRD response-adapted consolidation leads to high rate of MRD negativity in NDMM. For patients with 0 or 1 HRCA, this strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance."

Journal • Minimal residual disease • Residual disease • Cardiovascular • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Transplantation • Venous Thromboembolism

Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial. (PubMed, Nat Med) - P1/2 | "The two-part ALGONQUIN trial evaluated various doses and schedules of the anti-BCMA antibody-drug conjugate belantamab mafodotin plus pomalidomide and dexamethasone for patients who are lenalidomide refractory and proteosome inhibitor exposed. Belantamab mafodotin plus pomalidomide and dexamethasone induced durable responses with promising overall survival in relapsed multiple myeloma, the results of which are yet to be confirmed in the phase 3 DREAMM-8 study. ClinicalTrials.gov Identifier: NCT03715478 ."

Journal • P1/2 data • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Ophthalmology • Thrombocytopenia

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. (PubMed, J Clin Oncol) - "Lenalidomide improved efficacy of rituximab in patients with recurrent indolent lymphoma, with an acceptable safety profile."

Clinical • Journal • P3 data • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immune Modulation • Immunology • Inflammation • Leukopenia • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology

Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). (ASCO 2024) - P3 | "Isa-VRd significantly deepened responses including a significant increase of the MRD negative rate at 10 -5 vs IsaRd. The safety profile is consistent with addition of bortezomib. This study supports Isa-VRd as a new standard of care for NDMM TI non-frail patients."

Clinical • P3 data • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Treatment of Higher-Risk Myelodysplastic Syndrome With High-Dose Chemotherapy Followed by Lenalidomide and Azacitidine: A 4-Year Survival Update (SOHO 2026) - "Standard therapies include the hypomethylating agents azacitidine and decitabine...We offered our patients induction chemotherapy including cytarabine 3 g every week for 8 consecutive weeks followed by azacitadine 75 mg/m2 per day for 5 consecutive days per 28-day cycle, concomitant with lenalidomide 10 mg/day continuously... The combination of induction chemotherapy followed by hypomethylating agents plus immunomodulators seems to be a good choice in low income countries in treatment of higher-risk MDS patients."

Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Incidence and Baseline Predictors of Venous Thromboembolism in Isa-VRd and VRd Arms of the Phase 3 IMROZ Trial in Patients with Transplant Ineligible Newly Diagnosed Multiple Myeloma (Ti NDMM) (IMS 2026) - P3 | "Isatuximab plus bortezomib, lenalidomide, and dexamethasone (Isa-VRd) showed improved efficacy and safety vs VRd in the Phase 3 IMROZ trial (NCT03319667; median follow-up: 60 months [mo]) and is approved for Ti NDMM pts. These findings support VTE safety in using IMID-containing quadruplet therapy in NDMM pts, with Isa-VRd associated with lower VTE rates and cumulative incidence vs VRd from induction to 60 mo. Elevated BMI was identified as a potential baseline VTE predictor. These findings support Isa‑VRd as a standard of care in Ti NDMM."

Clinical • P3 data • Cardiovascular • Hematological Malignancies • Multiple Myeloma • Transplantation • Venous Thromboembolism

A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma (IMS 2026) - P1/2 | "If combined with daratumumab, etenta will be initiated as from C1D8, while lenalidomide and carfilzomib will be initiated from C2D1. This trial in progress highlights ongoing efforts to develop novel therapies for MM to improve pt outcomes."

Clinical • Combination therapy • IO biomarker • Monotherapy • P1/2 data • Hematological Malignancies • Multiple Myeloma

Addition of Acalabrutinib to Lenalidomide and Rituximab Induces High Complete Response Rates in Patients with Previously Untreated Follicular Lymphoma: Results of a Phase II Study (ASH 2023) - P2 | "Our results indicate that the addition of acalabrutinib to R2 is a safe and effective frontline non-chemotherapy regimen for FL patients, resulting in high CR rates, and induces favorable biological changes in multiple circulating immune cells. Since CRs occurred early, the study has been amended to include 26 additional patients who will be treated with only 6 cycles of aR2."

Clinical • P2 data • Anemia • Dermatology • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Oncology • CD4

Mezigdomide, Carfilzomib, and Dexamethasone (Mezikd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial (IMS 2026) - P3 | "Introduction: Patients (pts) entering second-line treatment (tx) are increasingly anti-CD38 mAb- and lenalidomide (LEN)-exposed, limiting tx options...Median (range) age was 68 (30–85) y with 25.1% of pts ≥75 y; median (range) number of prior LOTs was 2 (1–9); 92.1% of pts were triple-class-exposed, with 85.8% refractory to an anti-CD38 mAb and 75.8% to LEN; 37.2% were exposed to pomalidomide and 7.3% to anti-BCMA tx... MeziKd showed a clinically meaningful PFS benefit as early as first relapse in predominantly triple-class-exposed, anti-CD38 mAb- and LEN-refractory pts, a population with significant unmet need. These data support Mezi, a potent oral tx with a predictable and manageable safety profile, as a readily accessible potential new standard of care for RRMM across multiple settings."

P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • IKZF1

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma. (PubMed, Blood Cancer J) - No abstract available

Journal • P1/2 data • Hematological Malignancies • Multiple Myeloma • Oncology

Final results of a phase I trial of evorpacept (ALX148), lenalidomide, and rituximab for patients with B-cell non-Hodgkin lymphoma (AACR 2025) - P1/2 | "The combination of evorpacept and R2 has a safe toxicity profile, promising anti-tumoral activity (historical CR rate 30%), and induces favorable biological effects on multiple components of the tumoral immune microenvironment. A phase 2 study investigating its efficacy in pts with previously untreated and high tumor burden iNHL has completed enrollment."

Clinical • Late-breaking abstract • P1 data • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • SIRPA

Frequency and Characteristics of Longer Than 15 Years of Survival Following Triplet Based Induction and Autologous Stem Cell Transplantation: Prospective Dual-Center Real World Evidence (IMS 2026) - "As Lenalidomide maintenance treatment approval and reimbursement dates to 2023, this cohort excludes role of post-induction/ASCT treatment strategies... This dual center prospective RWE demonstrates durable long-term treatment-free and MRD(-) remission is possible following triplet based induction (suboptimal regimen in today's standards) and unmaintained ASCT. Factors associated with long-term survivorship are age and ISS at diagnosis in addition to PFS-1. These results are highly promising as current treatment strategies induce deeper and longer responses."

Clinical • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Transplantation

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. (PubMed, J Clin Oncol) - "Isa-KRd effectively induces high rates of sustainable MRD negativity in the difficult-to-treat HRNDMM population, regardless of transplant status, translating into a median PFS that was not yet reached after 44/33 months."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. (ASCO 2025) - P1/2 | "Funded by Bristol Myers Squibb Clinical Trial Registration Number: NCT02773030 Background: Lenalidomide (LEN), bortezomib (BORT), and dexamethasone (DEX) are recommended for NDMM. With longer follow-up (13–25 mo), IberVd confirmed durable deep responses, with ≥ CR % rising from 56.3% to 75.0%, and an encouraging safety profile with no new signals in pts with TNE NDMM. These data support IberVd evaluation in the frontline setting."

Fatigue • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Pain • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplantation

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a (ASH 2025) - P2 | "The IFM2021-01 trial is a phase 2study evaluating the doublets teclistamab-daratumumab (Cohort A) and teclistamab-lenalidomide(Cohort B) in frontline transplant-ineligible patients...Daratumumab SC (1800 mg) was given weekly in Cycles 1–2, every 2 weeks inCycles 3–6, and every 4 weeks thereafter...Conclusions. IFM2021-01 Cohort A demonstrates that an "all-antibody–based" doublet regimen ofteclistamab and daratumumab is highly effective and well-tolerated in elderly patients with NDMM, withdeep responses, high MRD negativity, and a favorable safety profile."

Clinical • Combination therapy • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia

Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Analysis of GRIFFIN (IMW 2022) - P2 | "In the final analysis of GRIFFIN (median followup, 49.6 mo), addition of DARA to RVd led to a clinically meaningful PFS benefit favoring the D-RVd arm. No new safety concerns occurred with longer follow-up. These data support use of D-RVd induction/consolidation and D-R maintenance as a new standard of care in transplant-eligible NDMM."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Transplantation

Correlation Between Mobilization Regimen and CD34+ Stem Cell Yield in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Analysis (SOHO 2026) - "Interventions: Mobilization regimens included cyclophosphamide plus G-CSF (n = 17); cyclophosphamide plus G-CSF with plerixafor rescue for poor mobilization (n = 8); upfront cyclophosphamide/G-CSF/plerixafor (n = 2); cytarabine plus G-CSF (n = 2); etoposide plus G-CSF with or without plerixafor (n = 2); rescue G-CSF plus plerixafor alone (n = 1); and other complex salvage strategies (n = 1). Cyclophosphamide plus G-CSF with ondemand plerixafor rescue achieved a 100% minimum-yield success rate. Greater lenalidomide exposure was associated with reduced CD34+ yield, supporting earlier mobilization in heavily pretreated patients. Prospective validation in larger cohorts is warranted."

Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology • CD34